09:10 AM EDT, 08/30/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Friday that its DehydraTECH-processed Rybelsus weight loss capsules showed more tolerability in delivering the GLP-1 drug semaglutide than commercially available Rybelsus in their second human pilot study.

The study revealed that none of the nine participants who took the DehydraTECH-processed Rybelsus capsules experienced any adverse events, whereas six out of nine participants who took the Rybelsus tablet reported mild adverse events, the company said.

The study also looked into an in-mouth dissolvable tablet form of the DehydraTECH-processed Rybelsus, which produced promising blood concentration results, achieving 32.3% to 106.9% of the Rybelsus tablet's effectiveness, the company said.

Price: 3.2600, Change: +0.03, Percent Change: +0.93